Download PDF
Semin Thromb Hemost
DOI: 10.1055/a-2546-0441
Original Article

Factor Inhibitor Testing: An Update from Australasia/Asia-Pacific

Emmanuel J. Favaloro 
1   Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research (ICPMR), Westmead Hospital, Westmead, NSW, Australia
2   Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia
3   School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, NSW, Australia
,
Sandya Arunachalam
4   RCPAQAP Haematology, St Leonards, NSW, Australia
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

Factor VIII (FVIII) inhibitors represent antibodies that develop against coagulation FVIII and reduce FVIII functional activity. FVIII inhibitors may develop in patients with congenital hemophilia A (CHA) in response to infused FVIII (allo-antibodies) or in patients without CHA in a variety of situations (auto-antibodies; acquired hemophilia A). We report updated findings for FVIII inhibitor testing in our geographic region using recent data (testing for the past 5 years; 2020–2024 inclusive) from the RCPAQAP (Royal College of Pathologists of Australasia Quality Assurance Program), an international external quality assessment (EQA) program, with over 80 enrolments for the FVIII inhibitor module. Four samples are assessed each year, with these comprising both FVIII inhibitor negative samples and FVIII inhibitor positive samples with various inhibitor titers. This EQA data largely evidences favorable findings in FVIII inhibitor testing in our jurisdiction, with >99% of test results interpreted correctly by participants for the presence (“detected”) or absence (“not detected”) of FVIII inhibitors in assessed samples. Moreover, most errors in interpretation appear to be transcription or data entry errors rather than analytic errors. The coefficient of variation (CV) values for FVIII inhibitor samples were moderately high, ranging from 25 to 40%, irrespective of the inhibitor titer (range: 3–64 Bethesda units [BU]/mL) or the method (i.e., Bethesda vs. Nijmegen). In conclusion, most laboratories were able to correctly identify the presence versus absence of FVIII inhibitors, although laboratory-reported titers varied moderately.

Keywords

factor VIII inhibitor testing - Bethesda assay - Bethesda unit - Nijmegen Bethesda assay - laboratory testing - external quality assessment - proficiency testing - assay variability

Authors' Contributions

Both authors contributed to various elements of the study execution, study design, and data analysis. E.J.F. wrote the original draft of the manuscript; both authors contributed to revision and approved the manuscript for submission and publication.




Publication History

Received: 17 February 2025

Accepted: 24 February 2025

Accepted Manuscript online:
27 February 2025

Article published online:
07 April 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Favaloro EJ, Curnow J, Pasalic L. Laboratory assessment of factor VIII inhibitors: when is it required? A perspective informed by local practice. J Clin Med 2024; 14 (01) 13
    PubMedSearch in Google Scholar
  • 2 Adcock DM, Favaloro EJ. Pearls and pitfalls in factor inhibitor assays. Int J Lab Hematol 2015; 37 (Suppl. 01) 52-60
    CrossrefPubMedSearch in Google Scholar
  • 3 Coppola A, Favaloro EJ, Tufano A, Di Minno MN, Cerbone AM, Franchini M. Acquired inhibitors of coagulation factors: part I-acquired hemophilia A. Semin Thromb Hemost 2012; 38 (05) 433-446
    Thieme ConnectPubMedSearch in Google Scholar
  • 4 Favaloro EJ, Gosselin RC, Pasalic L, Lippi G. Hemostasis and thrombosis: an overview focusing on associated laboratory testing to diagnose and help manage related disorders. Methods Mol Biol 2023; 2663: 3-38
    CrossrefPubMedSearch in Google Scholar
  • 5 Kershaw G. Detection and measurement of factor inhibitors. Methods Mol Biol 2017; 1646: 295-304
    CrossrefPubMedSearch in Google Scholar
  • 6 Kershaw G, Favaloro EJ. Laboratory identification of factor inhibitors: an update. Pathology 2012; 44 (04) 293-302
    CrossrefPubMedSearch in Google Scholar
  • 7 Favaloro EJ, Verbruggen B, Miller CH. Laboratory testing for factor inhibitors. Haemophilia 2014; 20 (Suppl. 04) 94-98
    PubMedSearch in Google Scholar
  • 8 Favaloro EJ, Bonar R, Duncan E. et al; RCPA QAP in Haematology Haemostasis Committee. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006; 96 (01) 73-78
    PubMedSearch in Google Scholar
  • 9 Favaloro EJ, Bonar R, Duncan E. et al. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007; 39 (05) 504-511
    CrossrefPubMedSearch in Google Scholar
  • 10 Favaloro EJ, Bonar R, Kershaw G, Duncan E, Sioufi J, Marsden K. Investigations from external quality assurance programs reveal a high degree of variation in the laboratory identification of coagulation factor inhibitors. Semin Thromb Hemost 2009; 35 (08) 794-805
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Favaloro EJ, Bonar R, Kershaw G, Mohammed S, Duncan E, Marsden K. RCPA Haematology QAP Haemostasis Committee. Laboratory identification of factor VIII inhibitors in the real world: the experience from Australasia. Haemophilia 2010; 16 (04) 662-670
    CrossrefPubMedSearch in Google Scholar
  • 12 Bonar RA, Favaloro EJ, Marsden K. External quality assessment of factor VIII inhibitor assays. Semin Thromb Hemost 2013; 39 (03) 320-326
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment program of the ECAT foundation. Semin Thromb Hemost 2009; 35 (08) 786-793
    PubMedSearch in Google Scholar
  • 14 Batty P, Riddell A, Kitchen S. et al. Factor VIII/IX inhibitor testing practices in the United Kingdom: results of a UKHCDO and UKNEQAS national survey. Haemophilia 2021; 27 (03) 490-499
    PubMedSearch in Google Scholar
  • 15 Adcock DM, Mammen J, Nair SC, de Lima Montalvão SA. Quality laboratory issues in bleeding disorders. Haemophilia 2016; 22 (Suppl. 05) 84-89
    PubMedSearch in Google Scholar
  • 16 Kershaw GW, Chen LS, Jayakodi D, Dunkley SM. Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors. Thromb Res 2013; 132 (06) 735-741
    PubMedSearch in Google Scholar
  • 17 Verbruggen B, Dardikh M, Polenewen R, van Duren C, Meijer P. The factor VIII inhibitor assays can be standardized: results of a workshop. J Thromb Haemost 2011; 9 (10) 2003-2008
    CrossrefPubMedSearch in Google Scholar
  • 18 Dardikh M, Meijer P, van der Meer F, Favaloro EJ, Verbruggen B. Acquired functional coagulation inhibitors: review on epidemiology, results of a wet-workshop on laboratory detection, and implications for quality of inhibitor diagnosis. Semin Thromb Hemost 2012; 38 (06) 613-621
    PubMedSearch in Google Scholar
  • 19 Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P. NASCOLA Proficiency Testing Committee. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009; 131 (04) 552-558
    PubMedSearch in Google Scholar
  • 20 Favaloro EJ, Arunachalam S, Dean E. et al. Activated protein C resistance testing: an update from Australasia/Asia-Pacific. Int J Lab Hematol 2025;
    CrossrefPubMedSearch in Google Scholar